Tuesday, 14 January 2020

Intussusception Market to Observe Strong Development by 2019

Intussusception Market Information: By Type (Ileoileal, Ileocolic, Ileo-Ileo-Colic), Diagnosis (Barium Enema, Ultrasound, X-Ray, Computerized Tomography (CT)), Treatment (Surgery, Drugs, Others), End User (Hospitals & Clinics) - Global Forecast till 2023
Market Scenario
According to the National health statistics, intussusception affects about 1 in every 1,900 children in the US. Its incidence is more common in children between one to five months, peaking at four to nine months of age, and then gradually declines at around 18 months. Intussusception affects boys and girls, with a ratio of approximately 3:1.
The global intussusception market is expected to reach USD 6.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Intussusception, also called bowel obstruction, is a potentially life-threatening condition caused by folding of one part of the intestine into another part, which causes a blockage in the intestine. The blockage hamper the excretion process. Intussusception is dominant in children of age 2 months-2 years. However, adults may also be affected by the intussusception. It commonly occurs where the small and large intestines meet. Additionally, it can occurs due to various causes such as tumors, inflammation, Meckel's diverticulum, duplication, appendix, hyperplasia of Peyer's patches, intestinal surgery, polyps, tumors, inflammation, etc.
It block the blood supply to intestine and causes tissue death. Tissue death can lead to infection, internal bleeding, tearing, damage to the intestines, and peritonitis. The primary symptoms of intussusception include acute abdominal pain, vomiting, nausea, lethargy, blood or mucus in the stools, constipation, etc. The risk factors for intussusception are age, sex, abnormal intestinal formation at birth, a family history, etc.
The market is growing at a very steady pace. Companies are opting various business strategies to capture a reasonable amount of share in the market. Product development represents the best strategy for dominating the market as surgery is the definitive treatment for intussusception market. The advent of minimally invasive treatment and diagnostic techniques such as computed tomography has changed the market landscape for to a large extent. Miniaturization of surgical instruments and development of minimal invasive treatment such as robotic laparoscopy is expected to drive the future market in the developed regions of North America and Europe. The cost of the product will be a decisive factor in the developing regions such as Asia Pacific and, especially, Africa. The growing demand for better minimally invasive surgical procedures is the greatest unmet need of the market.
The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global intussusception market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.
Key Players in the Global Intussusception Market
Some of the key players profiled in the report are Pfizer, Inc., Janssen Pharmaceuticals, Inc., Abbott, GlaxoSmithKline plc, sanofi-aventis U.S. LLC. , Novartis AG, Bayer AG, FUJIFILM Holdings Corporation, General Electric Company, Shimadzu Corporation, Carestream Health, Bristol-Myers Squibb Company, and others.
Segments of Global Intussusception Market
The global intussusception market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on the type, the market has been segmented as Ileoileal, Ileocolic, Ileo-ileo-colic, and others.
Based on the surgery, the market has been segmented as surgery, drugs, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Based on the diagnosis, the market has been segmented as barium enema, ultrasound, X-ray, computerized tomography (CT), and others.
Posted by at No comments:

Bronchoscopes Market, Segments, Growth and Value Chain 2019

Bronchoscopes Market Information, By Types (Rigid Bronchoscopes, Flexible Bronchoscopes), Application (Diagnosis (Examination, Tissue Specimen for Biopsy), Surgical Procedure), End User (Hospitals & Clinics, Diagnostic Centers) - Global Forecast till 2023
Market Scenario
Bronchoscopy has become an essential part of modern medicine. The examination by bronchoscopy has become the most common method to diagnose any kind of abnormality in the normal function of the respiratory system. Bronchoscopes are the instruments used for visualizing the insides of the patient’s airways. Bronchoscopes are usually inserted through nose or mouth, and occasionally through the trachea. Owing to the recent advances in medicine, a number of bronchoscopes have been introduced. Flexible bronchoscopes have been introduced to diagnose the diseases in trachea and the bronchi. Due to their different advantages, they are widely accepted throughout various countries and regions. The global bronchoscope market is majorly driven by increasing prevalence of respiratory tract diseases for instant, lung cancer and COPD, increasing number of bronchoscopies procedures, and increasing preference for minimally invasive procedures.
According to the WHO (World Health Organization), in 2015, 64 million people have chronic obstructive pulmonary disease (COPD), whereas, over 3 million people died of COPD. Additionally 1.8 million people across the globe were suffering from lung cancer. Increasing number of healthcare organization and patient inflow have boosted the number of bronchoscopy procedures. Moreover, increasing geriatric population, increasing healthcare expenditure, and changing environmental condition have fuelled the growth of the market over the review period. However, high cost of the devices and risk of infection may slow the growth of the market.
The market for bronchoscopes is growing at a healthy pace. The market is expected to grow at the CAGR of 7.4% during the forecast period and is estimated to reach USD 2,244.4 million by 2023.
Segmentation                                                                                                                                     
The global bronchoscopes market is segmented on the basis of types, application, and end users.
On the basis of types, the market is segmented into rigid bronchoscopes, and flexible bronchoscopes. Flexible bronchoscopes are further sub-segmented into fiber optic bronchoscopes, and video bronchoscopes.
On the basis of application, the market is segmented into diagnosis, and surgical procedure. Diagnosis is further segmented into examination, patient’s airways, bleeding lungs, possibility of lung cancer, chronic cough, and obtain tissue specimen for biopsy. Surgical procedure is further segmented into removal of a foreign object in the airway, laser resection of tumors, lung abscess, stent insertion, percutaneous tracheostomy, and tracheal intubation.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers and others.
Regional Analysis                     
Considering the global scenario of the market, America dominates the global bronchoscopes market owing to the presence of huge patient population, high healthcare spending and well developed healthcare sector.
North America holds the largest market share in the American bronchoscopes market. According to the Centers for Medicare & Medicaid Services, in 2015, U.S. healthcare spending increased 5.8% during last few years. Additionally, increasing government support for research & development have fueled the market growth of the American bronchoscopes market. Europe has the second largest market for the bronchoscopes which is followed by Asia Pacific. Due to the presence of a well-developed healthcare sector, increasing prevalence of respiratory diseases and high healthcare spending, the bronchoscopes market in Europe is growing at a CAGR of 6.9%. Asia Pacific is also witnessing a rapid growth in this market which is mainly due to rapidly increasing awareness about the availability of the treatment, increasing patient inflow, huge population base, and rising healthcare expenditure. The Middle East & Africa is expected to have limited growth. Middle East is dominating this market by holding major share of the Middle East & Africa market owing to the well developed technology and healthcare sector.
Key Findings:
  • Flexible bronchoscopes segment accounts for the largest market share in the global bronchoscopes market and is expected to be the fastest growing market with the CAGR of 8.0 % during the forecast period.
  • Diagnosis commanded the largest market share in 2016 and was valued at USD 885.7 million in 2016 and is expected to reach at USD 1,484.2 million by 2023.
  • On the basis of end users, Hospitals & clinics segment accounts for the largest market share of 49.1% in the global bronchoscopes market.
  • The Americas bronchoscopes market is expected to reach USD 868.7 million by 2023, at a CAGR of 7.4 % during the forecast period.
Key Players for Global Bronchoscopes Market
Some of the major players in this market are: Ambu Inc. (US), Boston Scientific Corporation (US), Cogentix Medical (US), Fujifilm Holdings Corporation (Japan), Olympus Corporation (Japan), Pentax Medicals (Japan), and KARL STORZ GmbH & Co. KG (Germany), Schindler Endoskopie Technologie Gmbh (Germany), Schölly Fiberoptic Gmbh (Germany), Vimex Sp. (Poland), Hangzhou EndoTop Medi-Tech Co., Ltd.(China), Guangzhou MeCan Medical Limited (China), and LocaMed (UK).
Posted by at No comments:

Intraductal Papilloma Market Segmentation Detailed Study with Forecast Up To 2019

Intraductal Papilloma Market Information: By Type (Central/Solitary, Peripheral/Multiple), Diagnosis (Mammogram, Biopsy, Ultrasonography, Computerized Tomography (CT)), Treatment (Microdochectomy, Total Duct Excision), and End User - Global Forecast till 2023
An intraductal papilloma is a benign, or noncancerous, breast tumour that forms in a milk duct and is made of gland and fibrous tissue as well as blood vessels. These generally appear as lumps after breast examination and may cause nipple discharge or bleeding. Intraductal papilloma most commonly occur in women between ages 35 and 55. Central/solitary papillomas are generally benign while multiple papillomas, have been associated with a slightly higher risk of breast cancer.
The market for global intraductal papilloma is constrained by the lack of awareness, high cost of surgery, complications of the surgery, lack of focus on women health in the developing and poorer regions of the world etc. Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to minimal invasive surgeries procedures such as needle aspiration biopsy surgeries etc.
The symptoms of intraductal papilloma are breast enlargement, inversion of the nipple, thickening or swelling of part of the breast, changes to the breast or nipple skin area, such as dimpling, redness, scaling, peeling etc. Multiple papillomas consist of about 10 % of all intraductal papillomas. Intraductal papilloma comprise approximately 10% of all benign breast tumour types and are benign lesions with an incidence of approximately 2-3% in humans. Risk factors such as obesity, alcohol consumption, postmenopausal hormone therapy, having the first child after the age of 35, or never having a child, medications containing estrogen and progesterone such as birth control pills, menstrual cycle abnormalities, physical inactivity, not breastfeeding the child etc. increase the chances of intraductal papillomas.
The global intraductal papilloma market is expected to reach USD 8.4 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Segments:
The global intraductal papilloma market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as central/solitary papillomas, peripheral/multiple papillomas and others.
Based on diagnosis, the market has been segmented as examination, ultrasonography, biopsy, mammogram/galactography, ductograms, Computerized Tomography (CT) and others.
Based on surgery, the market has been segmented as microdochectomy, total duct excision, drugs and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
The Americas account for a significant market share owing to extensive volume of surgeries performed and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drive the intraductal papilloma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US spends high on its healthcare, which accounts for 16% of GDP, further cruising the market for intraductal papilloma treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Global Intraductal papilloma Market
Some of key players profiled in the report are Allergen plc, Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals Inc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others.
Posted by at No comments:

Top trends in Healthcare Revenue Cycle Management Market by 2019

Healthcare Revenue Cycle Management Market Size analysis, by Product Type (Integrated, Standalone Software) Component (Software, Services) Deployment (On Premise, Cloud Based) End-user (Hospital, Ambulatory Service)- Global Forecast Till 2027
Market Scenario
Market Research Future Published a Cooked Research Report on Healthcare Revenue Cycle Management Market Research Report – Forecast to 2027.
Healthcare revenue cycle management (RCM) is a software that manages and simplifies all administrative and clinical functions including claims process, payment, revenue generation, patient registration, medical documentation, insurance verification, and accounts receivable & collections. Healthcare revenue cycle management software has gained profound importance in the healthcare sector in recent years. The global healthcare revenue cycle management market is anticipated to register a CAGR of 12.2% over the forecast period of 2017-2027, asserts Market Research Future (MRFR) in a detailed research report.
Towering costs of surgeries and overall healthcare has prompted hospitals to resort to technologies to reduce burden. Simplification of financial transactions is a key growth motivator which has spurred the adoption of RCM software among hospitals. In addition, expansion of healthcare budget and increase in a number of hospital chains and healthcare services across the globe fares well for the market. RCM software allows healthcare institutions to not only increase accuracy and timeliness but also helps them adhere to continuously evolving regulatory norms. RCM software can be applied to every aspect of the revenue cycle and is gaining traction among healthcare institutions.
On the downside, the growth of the global healthcare revenue cycle management market might be deterred by a dearth of trained healthcare professionals to operate the software. The global healthcare revenue cycle management market is anticipated to reach USD 1,75,163.5 Mn by the end of 2027.
Key Players for Global Healthcare Revenue Cycle Management (RCM) Market
  • Epic Systems Corporation (US),
  • McKesson Corporation (US),
  • Cerner Corporation (US),
  • General Electric Company (US),
  • Allscripts (US),
  • Quest Diagnostic (US),
  • Siemens Healthcare (Germany),
  • AdvantEdge Healthcare Solutions (US),
  • CareCloud (US),
  • Acelerartech (US),
  • 3M (US).
Intended Audience
  • Healthcare Revenue Cycle Management (RCM) Products Manufacturers
  • Healthcare Revenue Cycle Management (RCM) Products Providers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Segmentation
The global healthcare RCM market is segmented on the basis of deployment, component, product types, and end users.
On the basis of deployment, the market is segmented into on-premises, and cloud-based.
On the basis of component, the market is categorized into services, and software.
On the basis of product types, the market is divided into integrated software, and standalone software.
On the basis of end users, the market is shared into hospitals, ambulatory services and others.
Browse more Healthcare IT Reports @
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Posted by at No comments:
Labels:

Esophageal Cancer Market, Segments, Growth and Value Chain 2019

Global Esophageal cancer Market Information; By Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Others); By Phases (Phase I, Phases II and Phases III); by Treatment (Surgery, Chemotherapy and radiotherapy and Other) - Forecast to 2023
Esophageal Cancer Market Scenario:
Cancer is one of the leading causes of death worldwide and is expected to witness the expansion of patient population in the years to come. One of the types of cancer that affect the food pipe connecting the mouth and stomach is the esophageal cancer which is majorly prevalent among the older adults belonging to 55 years and above age group. Market Research Future (MRFR) has found out that the global esophageal cancer market is projected to grow at a compound annual rate of 8.7% during the forecast period 2017 to 2023. It is underlined in the report that the market is anticipated to scale a decent valuation of USD 1000.1 Mn towards the close of 2023.
The rising burden of cancer has paved the way for innovation in the market. It is one of the prime areas of research in the medical field. With the increasing number of drug patent applications in conjunction with the rising count of clinical trials, the esophageal cancer market is expected to witness a boom over the next couple of years. Key players are anticipated to exponentially invest in the development of more effective treatments which is forecasted to aid the proliferation of the esophageal market in the foreseeable future.
Addiction to tobacco, betel nuts, etc. is the key factor responsible for triggering esophageal cancer. Increasing shift towards a sedentary lifestyle has led to an increase in addiction problems among the masses. This, in turn, is expected to catalyze the growth of patient population. The future trajectory of the esophageal market is likely to remain highly lucrative over the next couple of years.
People are getting increasingly aware of the availability of treatments which is poised to aid market expansion. The support extended by governments in conjunction with the early detection of the disease has unleashed massive opportunities for the market players. It is anticipated to augment the esophageal cancer market in the long run.
Segmentation:
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.
Intended Audience
  • Global Esophageal cancer solutions providers, manufacturers & suppliers
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Academic institutes and universities
Regional Analysis
The market of esophageal cancer is much higher in the Americas region attribute to high rate of tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. According to report published by American Cancer Society, in 2018, it is estimated that around 17,290 new cases of esophageal cancer diagnosed in Americas which include 13,480 of men and 3,810 of women and around 15,850 will be die. Additionally, In the United States, up to 200,000 people die each year from smoking-related illnesses that leads to incidence of esophageal cancer in this region. The government have more focus towards research and development for introducing the best treatment for their population.
Asia Pacific region are considering the growing market, owing to presence of huge population suffering with esophageal cancer. Whereas country like India and china are considering fastest growing region due to the high rate of tobacco and alcohol consumption which leads the incidence of esophageal cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their citizen. Whereas, the Middle East and Africa have low market due to his incapability of investment, Moreover, developing countries are still focusing on new drugs for the treatment of esophageal cancer, this gap between the developed and developing countries will present significant growth opportunity for the esophageal cancer market players in the coming years.
Europe is also consider huge market for esophageal cancer players, owing to present of huge population affected with disease. According to Cancer Research U.K, in 2014, esophageal cancer holds 2 percent of total cancer cases in United Kingdom. Government are more focusing to educate their public in order to minimize the patient’s population by educating them about the side effect of tobacco, alcohol etc.
Key players of Global Esophageal cancer Market:
  • Amgen
  • Eli Lilly and Company,
  • Hoffmann-La Roche,
  • Bristol-Myers Squibb Company,
  • Boehringer Ingelheim GmbH,
  • Bristol-Myers Squibb,
  • GlaxoSmithKline Plc.,
  • Novartis AG,
  • Johnson & Johnson,
  • Gilead Sciences,
  • Merck & Co.
Posted by at No comments:

Worldwide Africa Malaria Diagnosis & Treatment Market 2019 Outlook, top 10 Industry players comprehensive analysis and Forecast to 2023


Africa Malaria Diagnosis & Treatment Market Information, by Diagnosis (Rapid Diagnostic Tests (RDT’s), Molecular diagnostics, Microscopy), by Malarial Parasite (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae and Plasmodium Ovale) - Forecast till 2023
Market Scenario:
According to World Health Organization (WHO), the global incidence of malaria between 2010 and 2015, fell by 21% and the malaria mortality fell by 29%. However the African region carries a disproportionately high share of the global malaria burden and accounted for 90% of malaria cases and 92% of malaria deaths worldwide and sub-Saharan Africa accounted for 76% of malaria cases and 75% deaths globally.
Africa malaria diagnosis market to reach around $ 2418.92 million from $ 550 million in 2017, by the end of the forecast period at a CAGR of ~ 28.0 %. While the malaria treatment market will grow by a CAGR of 8.1% to reach around $ 7180.7 million from $ 4500.0 million in 2016.
The growth of government programs against malaria and the support given by international bodies such as WHO is also a market driver. The market barriers include high cost of imported malaria diagnostic kits, low penetration of healthcare in Africa, low per capita income, low number of healthcare professionals in Africa etc. The political causes include massive corruption, low political power of citizens especially in nondemocratic nations, civil war in regions such as Malawi etc.
Malaria is an infectious disease caused by parasitic protozoa of the Plasmodium type. The symptoms include fever, fatigue, vomiting, and severe headaches and may lead to seizures, coma, or even death if untreated. Malaria is primarily a disease of the tropical and subtropical regions. The carrier of malaria is the female anopheles mosquito and hence there is a seasonal variation in the cases of malaria. Most cases of malaria are caused by P. falciparum because other types of plasmodium such as P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
Segmentation:
Africa Malaria Diagnosis & Treatment Market has been segmented on the basis of technique which comprises rapid diagnostic tests (RDT’S), molecular diagnostics and microscopy. On the basis of malarial parasite; market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale.
Key Players
·         Alere Inc.
·         Access Bio Inc.
·         Premier Medical Corporation
·         Beckman Coulter/Danaher
·         bioMerieux
·         Novartis Diagnostics
·         Siemens Healthcare
·         Bio-Rad Laboratories, Cipla Inc.
·         Ipca Laboratories Ltd.
·         Uni-Med India
·         Pfizer Inc.
·         Sun Pharmaceutical Industries Ltd.
·         Sanofi
Regional Analysis
The healthcare sector of Africa is divided between private and state. The public healthcare expenditure accounts for approximately 48 % of total health expenditure in 2014 with variation in different countries. Local manufacturing represents a poor outlook which is limited to consumables and ordinary articles and there are a handful of high tech devices manufacturers. Africa is extremely dependent on imports for medical devices and imports account for approximately 90 % of total market for medical devices and Chinese medical device suppliers dominate the scenario. Among the regions of Africa, South Africa and Egypt account for 40 % of market. Other important nations are Nigeria, Morocco and Algeria. Collaboration with large global companies and technical transfer will remain the key strategy for developing the regional African market as can be seen by the example of China.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Posted by at No comments:

U.S. Personalized Medicine Market to Observe Significant Growth by 2019

U.S. Personalized Medicine Market Information, by product (diagnostic, therapeutics, medical care and nutrition and wellness) by application (diagnosis and intervention, drug development and usage, cancer genomics and others), by End users (hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio and health informatics companies and others)- Forecast to 2023 
Market Synopsis of U.S. Personalized Medicine Market:
An expert on premium research reports, Market Research Future has added a report titled " U.S. Personalized Medicine Market Research Report - Forecast To 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.
The Personalized Medicine Market is the most recent trend in the multibillion–dollar molecular diagnostics industry. Pharmaceutical and biotechnology companies are increasingly turning to personalized medicine in order to improve the drug development process and also to speed up the approval or sanction of new drugs.
The U.S. Personalized Medicine market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. A factsheet published by the WHO states that about 17.5 million people die due to cancer and other diseases every year, which is about 31% of the deaths across the globe. These alarming statistics are the obvious reason for growth of the U.S. Personalized Medicine market. Major factors driving the growth of this market include growing occurrence of autoimmune diseases during the forecast period and various other disease.
U.S personalized medicine market is expected to grow at the CAGR of 7.5% during the forecasted period.
Various trends are responsible for influencing the growth trajectory of the US personalized medicine market. Personalized medicine promises enormous potential in the treatment of cancer. Personalized medicine has entered the mainstream in the treatment of oncology diseases and is changing the way such diseases are identified, treated and classified. According to the World Health Organization (WHO), cancer is one of the prime reasons for 31% of the deaths globally and each year about 17.5 Mn people die due to cancer. Surging prevalence of cancer across the US is a prime reason for the growth of the US personalized medicine market.
Strong research & development activities in the field of personalized medicine by industrial, academic, and government agencies continue to remain strong in the region which also supports the growth of the US personalized medicine market.
Increasing incidences of autoimmune diseases stimulate the growth of the US personalized medicine market. Also, the government in the US is extending its support in the form of funding for R&D activities; favorable NIH policies create a conducive environment for the growth of the US personalized medicine market.
Furthermore, a growing number of companies from outside the health industry are entering the personalized medicine space which is likely to provide an impetus to the growth of the US personalized medicine market. 
Industry Updates
  • In December 2018, researchers at the University of Utah developed a novel personalized medicine tool for inherited colorectal cancer syndrome. The results for the same was published in the journal Genetics in Medicine.
  • In December 2018, researchers at the Columbia University have made advancements in personalized medicine that can be helpful in the treatment of kidney diseases.
Segmentation
The US personalized medicine market has been segmented based on product, application, and end user. By product, the US personalized medicine market has been segmented into diagnostic, therapeutics, medical care and nutrition, and wellness and others. The diagnostic and therapeutic segment accounts for the largest share of the market.
By application, the US personalized medicine market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others.
By end user, the US personalized medicine market has been segmented into hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio & health informatics companies, and others. End user-wise, the hospitals segment commands the largest share of the market owing to growing usage in hospitals. The molecular diagnostic laboratories and testing centers segment is the second largest segment.
Competitive Landscape
Personalized medicine is presenting new challenges as well as opportunities to the market players who are continually endeavoring make their mark in the market. Collaborations through mergers, acquisitions, partnerships, and others are key strategies utilized by the market participants to stay competitive and improve their product offerings. Sanofi, Pfizer Inc., Laboratory Corporation of America, Abbott, Becton Dickinson & Co., Quest Diagnostics, GE Healthcare,
CardioDx Inc., Asuragen Inc., Bristol-Myers Squibb, Siemens Healthcare Diagnostics Inc., are the notable players in the US personalized medicine market.
Posted by at No comments:
Subscribe to: Posts (Atom)